IL4 and COVID-19: A phase IIa trial demonstrated that dupilumab reduces the probability of admission to the intensive care unit for patients with moderate to severe COVID-19 and improves the survival rate of patients by disabling the signal transduction of IL-4 and IL-13 [27].